Novartis’ troubles over the Zolgensma data manipulation incident show no sign of lessening. The company is on the defensive again after it emerged a senior manager sold almost $1 million worth ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

Since 2020, the global SMA treatment landscape has progressed, with three treatments now approved, according to Novartis. Along with Zolgensma – which made its debut in 2019 – Biogen has had ...

In a statement to ProPublica, Novartis said Zolgensma’s price reflects its benefits to children with SMA and to society more broadly. “Zolgensma is consistently priced based on the value it ...

Novartis (NYSE:NVS) said a Phase 3 study of an intrathecal formulation of its gene therapy Zolgensma, also known as OAV101 IT ...

Zolgensma is a prescription drug that’s used to treat spinal muscular atrophy (SMA) in young children. Zolgensma’s cost may depend on factors such as your child’s treatment plan and whether ...

The company uses the facility to manufacture its spinal muscular atrophy gene therapy, called Zolgensma. Last year, Novartis reported revenue from Zolgensma of $1.2 billion.

Novartis’ Durham facility produces Zolgensma, which treats spinal muscular atrophy, an inherited fatal disorder often referred to as SMA. In 2019, the Food and Drug Administration approved ...

AveXis, a subsidiary of Novartis, knew about the manipulated data as early as March, two months before it was officially approved. AveXis manufactures the product in question, Zolgensma, which stands ...

The company uses the facility to manufacture its spinal muscular atrophy gene therapy, called Zolgensma. Novartis-owned firm picks Durham over Illinois, Ireland for 200 jobs Multibillion-dollar ...